A 35-year-old woman on combined oral contraceptive (COC) for 8 years presents with a 3-month history of breakthrough bleeding. She denies any missed pills, has no vaginal discharge or pelvic pain, and cervical examination is normal. Urine pregnancy test is negative. What is the most appropriate next step in management?

Explanation

## Clinical Context Breakthrough bleeding (BTB) on COCs is a common issue affecting 10–30% of users, especially in the first 3–6 months but also later. The differential includes pill compliance, drug interactions, endometrial pathology, and cervical lesions [cite:KD Tripathi 8e Ch 65]. ## Diagnostic and Management Approach ```mermaid flowchart TD A[Breakthrough bleeding on COC]:::outcome --> B{Pregnancy ruled out?}:::decision B -->|No| C[Urine/serum hCG]:::action B -->|Yes| D{Compliance adequate?}:::decision D -->|No| E[Counsel on timing, missed pills]:::action D -->|Yes| F{Pelvic exam findings?}:::decision F -->|Cervical lesion/discharge| G[Cervical cytology + colposcopy]:::action F -->|Normal| H[Pelvic ultrasound to exclude pathology]:::action H --> I{Structural lesion?}:::decision I -->|Yes| J[Refer for further management]:::urgent I -->|No| K[Reassure; consider pill-free interval adjustment or higher-dose COC]:::action E --> K G --> J ``` ## Key Point: **Breakthrough bleeding on COCs requires exclusion of pregnancy, compliance issues, and structural/cervical pathology before escalating hormone dose.** [cite:Harrison 21e Ch 327] ## Management Hierarchy | Step | Action | Rationale | | --- | --- | --- | | **1** | Rule out pregnancy | hCG negative confirms non-pregnant state | | **2** | Assess pill compliance | Missed pills are the most common cause of BTB | | **3** | Pelvic examination | Exclude cervical lesions, polyps, infection | | **4** | Pelvic ultrasound | Rule out endometrial hyperplasia, fibroids, adenomyosis | | **5** | Cervical cytology (Pap smear) | Screen for cervical pathology | | **6** | Adjust pill regimen or dose | Only after organic pathology excluded | ## Why Pelvic Ultrasound + Cervical Cytology? **High-Yield:** In a woman with 8 years of COC use and new-onset BTB, structural pathology (endometrial polyp, fibroid, adenomyosis) or cervical lesion must be excluded before attributing bleeding to hormonal insufficiency. Ultrasound is the first-line imaging; cervical cytology screens for dysplasia. ## Clinical Pearl: **Pill-free interval adjustment:** Some women benefit from shortening the pill-free interval (e.g., 4 days instead of 7) to reduce endometrial proliferation and BTB. This is safer than increasing estrogen dose in most cases. ## Why Not Immediate Dose Escalation? Higher-dose COCs (50 µg EE) increase thrombotic, cardiovascular, and metabolic risks without proven superiority over compliance counseling or regimen adjustment. They are reserved for persistent BTB after organic pathology is excluded [cite:WHO Medical Eligibility Criteria].